Freudenberg Medical has launched a new ISO Class 5 controlled cleanroom at its Kaiserslautern, Germany site to deliver washed, dried and gamma-sterilized single-use assemblies to biopharmaceutical customers, the company announced ahead of INTERPHEX 2026 in New York (April 21-23). The service, branded CleanAssure, is pitched at biomanufacturers looking to push more of the cleaning and…
Kincell Bio to expand North Carolina manufacturing site
Kincell Bio announced that it made a significant strategic investment in the expansion of its Research Triangle Park, North Carolina, facility. The contract development and manufacturing organization (CDMO) supports autologous and allogenic cell therapy programs. It expects the new expansion to support clients as they advance from late-stage clinical CMC development through commercialization and post-approval…
Trelleborg exhibits single-use solutions for biopharma customers at Interphex
NEWS RELEASE: Trelleborg exhibits single-use solutions for biopharma customers at Interphex Plymouth, Minnesota – Trelleborg Medical Solutions will exhibit advanced solutions for biopharmaceutical, pharmaceutical and cell and gene therapy applications at Interphex in New York City, April 21 – 23, 2026, at Booth No. 2159. On display is Trelleborg’s BioPharmaPro portfolio, including solutions for bioprocessing,…
West Pharmaceutical Services opens expanded Dublin facility for injectable therapies
West Pharmaceutical Services (NYSE:WST) announced the opening of a new facility for contract services in Dublin, Ireland. IDA Ireland, the foreign direct investment arm for the Irish government, shared the announcement of the Damastown site’s opening. The 165,000-square-foot expansion enhances West’s contract services. It helps meet the growing demand for high-volume treatments, including for diabetes…
Thermo Fisher, SHL Medical collab on drug delivery device production
Thermo Fisher Scientific today announced a strategic collaboration with drug delivery system provider SHL Medical. The collaboration coincides with the expansion of sterile fill-finish and auto-injector final assembly capacity at its Ridgefield, New Jersey site. Together, Thermo Fisher says its investments establish a fully integrated U.S.-based offering across sterile manufacturing, device assembly and commercial packaging…
Wilmington PharmaTech invests $50M in API manufacturing expansion
Wilmington PharmaTech announced a $50 million investment to expand its Delaware campus for active pharmaceutical ingredient (API) manufacturing. Newark, Delaware-based Wilmington PharmaTech said the expansion more than doubles its current API reactor capacity. It adds two new 10,000-liter reactor suites to increase commercial-scale manufacturing capabilities. This supports growing demand for high-quality, U.S.-based manufacturing as the…
Cambrex expands US, European API manufacturing footprint
Cambrex announced today that it achieved multiple milestones in its effort to expand its active pharmaceutical ingredient (API) manufacturing. East Rutherford, New Jersey-based Cambrex said it completed the initial engineering studies for a new, large-scale API manufacturing plant in Charles City, Iowa. It also added further investment to support its Milan, Italy, site. The latest…
Plastic Ingenuity expands operations into Europe with Spezi-Pack acquisition
Plastic Ingenuity announced today that it’s expanding its operations into Europe with the acquisition of Spezi-Pack. Located near Dresden, Germany, Spezi-Pack is an established thermoforming company. Madison, Wisconsin-based Plastic Ingenuity said the expansion enables it to offer regional European manufacturing for medical device and pharmaceutical packaging. The acquisition helps to increase efficiencies along the value…
BioDuro, Cenra launch joint venture for API manufacturing
BioDuro announced that it established a joint venture with Cenra API Solutions, also known as Chunghwa Chemical Synthesis & Biotech Co. The joint venture aims to combine the services of the CRDMO and a pharmaceutical chemical manufacturer. They hope to add significant commercial-scale active pharmaceutical ingredient (API) manufacturing capacity at Cenra’s campus in Taipei, Taiwan, to…
Novo Nordisk announces $507M GLP-1 manufacturing expansion in Ireland
Novo Nordisk today announced plans to invest €432 million ($507 million) in its facility in Monksland, Athlone, Ireland. The Danish pharmaceutical giant plans to add significant additional manufacturing capacity for current and future GLP-1 treatments. According to Novo Nordisk, the expansion of the tabletting facility further reinforces its long-term commitment to Ireland and global healthcare…